Review Article
The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck
Table 4
Summary of alternative Anti-EGFR monoclonal antibodies.
| Study | Year | Phase | Agent | Number of Patients/agent | Response (%)/Survival (months) |
| Locally advanced |
| Antibody + radiation |
|
Crombet et al. [31] | 2004 | I/II | Nimotuzumab | | CR 56 | DCR 88 | 3 yr OS 67 |
Rojo et al. [32] | 2010 | I | Nimotuzumab | | CR 20 | PR 70 | SD 10 | DCR 90 |
RodrÃguezet al. [33] | 2010 | II | Nimotuzumab | | CR 60 | OS 12.5 mo |
Babu et al. [34] | 2010 | II | Nimotuzumab | | 4 yr OS 34 |
| Antibody + chemoradiation |
|
Wirth et al. [35]
| 2010 | I | Panitumumab | ; paclitaxel/ carboplatin | CR 69 | PR 31 | SD 0 | DCR 100 |
Gupta and Madholia [36] | 2010 | I | Nimotuzumab | ; weekly cisplatin
| CR 59 | PR 18 | SD 12 | DCR 89 |
Babu et al. [34] | 2010 | II | Nimotuzumab | ; cisplatin | 4 yr OS 47 |
| Palliative |
|
Vermorken et al. [37] (SPECTRUM) | 2010 | III | Panitumumab | ; platinum therapy/5-FU | ORR 36 versus 25 | PFS 5.8 versus 4.6 | OS 11.1 versus 9.0 |
Machiels et al. [38]
| 2011 | III | Zalutumumab | ; optional methotrexate | DCR 48 versus 27 | ORR 6.3 versus 1.1 | PFS 2.5 versus 2.1
| OS 6.7 versus 5.2 |
Guo et al. [39] | 2011 | I | Nimotuzumab | ; cisplatin/docetaxel/5-FU | CR 6 | PR 55 | SD 25 | DCR 86 |
|
|
CR: complete response, PR: partial response, SD: stable disease, DCR: disease control rate (CR + PR + SD), ORR: overall response rate, PFS: progression-free survival, and OS: overall survival; *statistically significant; **high-dose treatment group.
|